1. Executive Summary This report provides a comprehensive analysis of Dupixent’s (dupilumab) pricing model to assess its viability as a […]
How a $37,000-a-year medicine sets a good model for drug pricing Read Post »
The pharmaceutical industry is a high-stakes arena, where innovation isn’t just a buzzword – it’s the lifeblood of progress, patient
3 big mistakes drug companies make in recruiting new employees Read Post »
Merck made $29.5 billion from a single drug last year. That drug, Keytruda, loses its primary patent in 2028. Read
The $236 Billion Cliff: How Pharma Loses Its Blockbusters—and What Replaces Them Read Post »
Executive Summary & The New Biologic Battleground The global pharmaceutical landscape is undergoing a seismic shift, driven by the confluence
The Biosimilar Gambit: Turning Patent Expirations into Market Dominance Read Post »
A deep-dive reference for pharma IP teams, R&D leads, and institutional investors on the science, strategy, and commercial mechanics of
Get fresh news and insights, drug patent expirations & more…
